为提升生物制造"技术研发—生产制造—市场推广"一体化发展能力，工业和信息化部组织开展了生 物制造标志性产品征集，经省级工业和信息化主管部门推荐及专家评价等程序，首批35项产品公布。山 东有华熙生物科技股份公司的透明质酸、山东润德生物科技有限公司的氨基葡萄糖、中国科学院青岛生 物能源与过程研究所的反式乌头酸三项产品入选。 工业和信息化部面向食品及添加剂、生物制药、化妆品、生物基化学品、生物能源、生物基材料、 酶制剂、天然产物生物合成、专用设备及材料等重点领域，征集技术水平先进、经济效益明显、推广价 值突出的标志性产品。据介绍，工业和信息化部将建立生物制造标志性产品库，对纳入名单的产品加大 宣传推广力度，通过现有政策渠道支持其提升生物制造产品技术创新能力、研发生产能力和市场推广能 力。（记者 付玉婷） ...

济宁高新区党工委书记、管委会主任王亚栋告诉记者，该区已高标准规划建设合成生物产业园，设立产 业发展基金，重点支持菌种创制、发酵工艺等核心环节攻关，通过构建"技术研发—场景应用—产业落 地"的闭环生态，聚力打造合成生物产业核心承载区与技术应用高地。 布局新赛道，济宁高新区的产业基础早已为合成生物的生根发芽备好了肥沃的土壤。作为国家级生物技 术产业基地，这里集聚了鲁抗医药、核芯医药、辰欣药业等一批龙头企业，逐步构建起从研发创新到规 模化制造的完整产业链。同时，先天的交通物流优势让产业发展如虎添翼。济宁高新保税物流中心 以"一站式通关、一体化监管"高效服务，进口环节支持企业将货物暂存中心、延缓缴纳关税等相关税费 并按需分批提货，出口环节允许企业在高新区完成报关、查验等流程，货物存入即视同出口，便捷享受 退税政策，大幅降低企业物流与时间成本。 11月25日，"智汇合成 驱动未来"合成生物产业发展交流会在济宁高新区举办，行业目光聚焦这片合成 生物产业的新兴之地。作为参会嘉宾，中国工程院院士、南京师范大学副校长黄和现场带来专题报告， 结合自身研究领域指出，合成生物学以微生物资源开发利用为核心，通过代谢工程调控与微生物改造 ...

Core Viewpoint - The company held a successful half-year performance briefing on September 19, 2025, with full interaction with investors, addressing various inquiries regarding stock issuance, project updates, and financial performance [1][2]. Group 1: Stock Issuance and Financial Performance - The company has submitted a registration application to the China Securities Regulatory Commission for a stock issuance to specific investors, following the Shanghai Stock Exchange's review [1][2]. - The pricing for the stock issuance will be no less than 80% of the average trading price over the 20 trading days prior to the pricing date [1][2]. - The company reported a significant profit decline in the first half of 2025, primarily due to non-recurring gains from asset disposals in the previous year, which amounted to 156 million [2][3]. Group 2: Project Updates - The trans-aconitic acid green bio-manufacturing project commenced production on May 29, 2025, marking a significant step towards industrialization [1]. - The company has over 60 biological pesticide products in production and sales, with three innovative biological pesticides currently under registration [1][2]. - The trans-aconitic acid pesticide formulation is in the testing phase, with plans to submit registration materials in the first quarter of 2026 [1][2]. Group 3: R&D and Product Development - The company has three I-class innovative drugs in clinical trials: TRN-157 for chronic obstructive pulmonary disease in Phase II, CIGB-814 for rheumatoid arthritis in Phase I, and CMS-203, a PDE5 inhibitor for male erectile dysfunction in Phase II [2][3]. - The company is focusing on enhancing operational efficiency and profitability to improve its investment value amidst a competitive pharmaceutical market [2][3].

Core Viewpoint - The collaboration between Qingdao Institute of Bioenergy and Process Research and Shandong Lukang Pharmaceutical has successfully developed a microbial green manufacturing technology for trans-aconitic acid, overcoming production challenges and achieving large-scale production, which has been recognized with a first-class award in Shandong Province for 2024 [1][3][12] Group 1: Production Challenges and Solutions - Trans-aconitic acid is a food additive with significant applications in agriculture, medicine, and chemicals, but traditional production methods face high costs and inefficiencies [3][9] - The research team developed an integrated technology system using industrial Aspergillus niger as a chassis cell, enabling the conversion of starch sugars into trans-aconitic acid through synthetic biology [3][5] - Key challenges addressed include the genetic modification of industrial strains, achieving high-efficiency synthesis, and optimizing fermentation processes for industrial application [5][7] Group 2: Industrial Application and Market Potential - The successful production of trans-aconitic acid opens up new avenues for its use as a biopesticide, particularly in combating root-knot nematodes in agriculture, aligning with national green agriculture initiatives [9][11] - In the chemical industry, trans-aconitic acid is being developed into a bio-based plasticizer, providing a safer alternative to petroleum-based phthalate plasticizers, which are facing regulatory restrictions due to health concerns [11][12] - The technology has garnered attention from various enterprises, leading to successful production demonstrations and positioning trans-aconitic acid as a key bio-based chemical in the upcoming 2024-2027 development plan for fine chemical industries [12]

Core Viewpoint - The company is advancing its "党建链" (Party Building Chain) to empower its "产业链" (Industrial Chain) by enhancing collaboration across innovation, industry, talent, and technology chains, aiming for high-quality development [2]. Group 1: Innovation Chain - The company is establishing a new model for collaborative innovation that includes "source innovation → technology development → achievement transformation → industrial application" through party building [2]. - Collaboration with the Chinese Academy of Sciences has led to the development of trans-aconitic acid, with significant contributions to innovation and talent exchange, culminating in a first-class award from Shandong Province for technological invention [2]. - The global first green bio-manufacturing project for trans-aconitic acid is set to commence production in June 2025 [2]. Group 2: R&D Chain - The company is creating a new collaborative model for R&D that focuses on "core technology breakthroughs → drug clinical applications → drug achievement transformation" [3]. - Joint efforts with China Pharmaceutical University and Peking University People's Hospital are enhancing the development of the innovative drug CIGB-814, which is expected to lead new directions in immunotherapy and cell therapy [3]. - The establishment of the "Innovative Drug Evaluation and Repositioning Laboratory" is a key initiative in advancing the research of CIGB-814 [3]. Group 3: Supply Chain - The company is enhancing upstream and downstream collaboration through party building, ensuring the stability and safety of its supply chain [5]. - Partnerships with companies like Sinopharm Holdings and Henan Renhua Biotech are driving sales growth through collaborative efforts [5]. Group 4: Professional Chain - The company is collaborating with various regulatory and research institutions to improve quality and compliance, thereby enhancing operational efficiency [6]. - Engagement with the Shandong Provincial Department of Ecology and Environment is facilitating the effective implementation of ecological policies and advanced technologies [6]. - The integration of party building with professional guidance is fostering a strong foundation for quality improvement and high-quality development [6].

Core Viewpoint - The successful launch of the world's first microbial green manufacturing project for trans-aconitic acid by Qingdao Energy Research Institute and Shandong Lukang Pharmaceutical Co., Ltd. marks a significant breakthrough in the accessibility of this important chemical raw material, which will effectively promote the rapid development of downstream applications such as bio-based materials and biopesticides [1][3]. Group 1: Project Overview - The project was officially launched on May 29, 2024, in Jining, Shandong, and is recognized for overcoming the challenges in microbial green manufacturing technology for trans-aconitic acid [1][3]. - The technology has been evaluated as internationally leading, with strong innovation and advanced indicators, suggesting further expansion of production and application scale [3][4]. Group 2: Technological Innovations - The project utilizes synthetic biology strategies to achieve microbial green manufacturing of trans-aconitic acid for the first time, employing high acid-resistant Aspergillus niger as the chassis cell [3][4]. - Key technological developments include enabling technology platforms, efficient cell factories, fermentation process demonstration, and separation and purification processes, leading to the establishment of the world's first demonstration line for microbial green manufacturing of trans-aconitic acid [3][4]. Group 3: Industry Impact - The collaboration between Qingdao Energy Research Institute and Lukang Pharmaceutical exemplifies interdisciplinary innovation in bio-chemical-materials integration, transforming disruptive technologies into new productive forces [4]. - The project has been recognized as a benchmark for green, low-carbon, and high-quality development, injecting new momentum into the bio-economy sector [5].

Core Viewpoint - The successful launch of the world's first microbial green manufacturing project for trans-aconitic acid by Qingdao Energy Institute and Shandong Lukang Pharmaceutical marks a significant breakthrough in the accessibility of this important chemical raw material, which will effectively promote the rapid development of downstream applications such as bio-based materials and biopesticides [1][3]. Group 1: Project Overview - The project was officially launched on May 29 in Jining, Shandong, and represents a major advancement in the microbial green manufacturing technology for trans-aconitic acid [1]. - The technology has been recognized as internationally leading, having overcome challenges in microbial green manufacturing, and has established the world's first demonstration line for this production method [3][4]. Group 2: Technological Innovations - The project utilized a high acid-resistant strain of Aspergillus niger as the chassis cell and developed key technologies including enabling technology platforms, efficient cell factories, fermentation process demonstration, and separation and purification processes [3]. - The successful scale-up of fermentation processes was achieved at a pilot level of ten tons, demonstrating the feasibility of large-scale production [3]. Group 3: Applications and Impact - The project has led to the development of environmentally friendly, safe, and economical new bio-based plasticizers derived from trans-aconitic acid, providing innovative solutions for sectors such as medical devices, electrical cables, and specialty rubber [4]. - The project has been awarded the highest prize at the first National Disruptive Technology Innovation Competition, showcasing its potential to lead industry innovation through technology [5].